Up-to-date of the role of sodium-glucose transporter 2 inhibitors in cardiovascular-kidney- metabolic syndrome
10.3760/cma.j.cn441217-20241104-01106
- VernacularTitle:钠-葡萄糖共转运蛋白2抑制剂在心血管-肾脏-代谢综合征中作用的研究进展
- Author:
Yan YANG
1
;
Min YANG
;
Bin WANG
;
Bicheng LIU
Author Information
1. 苏州大学附属第三医院肾内科，常州 213003
- Publication Type:Journal Article
- Keywords:
Sodium-glucose transporter 2 inhibitors;
Cardiovascular diseases;
Kidney diseases;
Metabolic syndrome;
Cardiovascular-kidney-metabolic syndrome;
Diabetic n
- From:
Chinese Journal of Nephrology
2025;41(11):889-894
- CountryChina
- Language:Chinese
-
Abstract:
The cardiovascular-kidney-metabolic syndrome (CKM) is a systemic disease caused by the interaction and mutual influence of cardiovascular diseases, chronic kidney disease, and metabolic abnormalities. It severely impairs patients' quality of life, increases the risk of death, and has become a serious global public health issue. Sodium-glucose transporter 2 inhibitor (SGLT2i) is a novel class of oral hypoglycemic agent with both cardiorenal protection and metabolic regulation effects. It has become an emerging strategy to prevent the onset, slow the progression, and improve the prognosis of CKM. This article provides a comprehensive review of the current applications of SGLT2i in CKM and their potential mechanisms for ameliorating metabolic risk factors and conferring cardio-renal protection, thereby offering a theoretical foundation for the clinical use of SGLT2i in patients with this newly defined critical clinical condition.
